Company / Capital Expenditures
Sunshine Biopharma Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$1.7M
FY2025
5-year range
$0 / $1.7M
FY2021-FY2025
Trend
+1914.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +1915% YoY in FY2025, a notable deviation from the 8-year average annual change of +261%.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +353.9%.
Improved from $193,982 to $2M over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +353.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +353.9%, indicating consistent growth.
- In FY2025, capital expenditures increased 1914.6% year-over-year.
- Lowest capital expenditures in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7M | +1914.6% |
| FY2024 | $82.3K | -57.6% |
| FY2023 | $194.0K | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $1.2K | +38.5% |
| FY2020 | $860 | -95.4% |
| FY2019 | $18.9K | +407.0% |
| FY2018 | $3.7K | +8.1% |
| FY2017 | $3.4K | -28.2% |
| FY2016 | $4.8K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026